EMMAC, Europe’s largest independent medical cannabis company, has announced the launch of its first line of unlicensed medicinal cannabis flower products for the UK market.
Just weeks after Curaleaf Holdings agreed to purchase EMMAC, EMMAC has partnered with Sapphire Medical Clinics to offer the high-THC prescription floral product to a limited number of UK patients. Data from prescriptions is used to collect patient and clinical feedback.
Sapphire’s data-driven approach will “inform” EMMAC product development to bring additional medicinal cannabis flower products to market in 2021 to meet identified patient needs.
By definition, the cannabis flower is the smokable part of the cannabis plant. To keep the product fresh and ready to eat, it should be stored in places where it is exposed to as little oxygen, heat, moisture or UV light as possible.
According to EMMAC, the new range of products will be manufactured in the UK and will be an extension of the existing range of medicinal cannabis oil products.
EMMAC’s vertically integrated business model, which includes cultivation, extraction, production and distribution, means that medical cannabis flowers are now more affordable for patients in the UK.
The unlicensed medical cannabis products are made by GMP at Rokshaw, EMMAC’s leading UK MHRA-approved specialist manufacturer.
Antonio Costanzo, CEO of EMMAC, said: “EMMAC is very pleased to expand its range of unlicensed medicinal cannabis products for the UK market by introducing high quality floral products.
“As a market leader, we focus on solving the most important challenges for patients and doctors in terms of price, access and sustainability of medical cannabis products.
“Driving innovation and efficiency through our vertically integrated business model means we are in complete control of our supply chain. This allows us to maintain strict quality control while achieving cost efficiencies that we can pass on to patients while building a robust and sustainable business. “